TrialBMC cancer2016

A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers.

Rafael B R León-Cachón et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.